Beta agonist use during asthma exacerbations: How much is too much?

New Zealand Medical Journal

Volumn 124, Issue 1332, 2011, Pages 77-80

  Patel, Mitesh ^a   Perrin, Kyle ^a   Beasley, Richard ^a  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL; PREDNISONE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG; VANNAIR;

ADULT; ARTICLE; ASTHMA; CASE REPORT; DISEASE CONTROL; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; INHALER; NEBULIZATION; TREATMENT PLANNING;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; IPRATROPIUM; PREDNISONE;

EID: 79955448314     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Wijesinghe M, Weatherall M, Perrin K, et al. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J. 2009;34:803-11.
2. Taylor DR, Jayaram L, Asher MI, Epton MJ. "As-required" combination therapy with inhaled corticosteroids and long-acting beta-2 agonists for asthma: current evidence and recommendations. N Z Med J 2008;121:106-118.
3. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6:204-10.
4. Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992; 21:737-44.
5. Holt S, Masoli M, Beasley R. The use of the self-management plan system of care in adult asthma. Prim Care Respir J 2004; 13:19-27.
6. Symbicort® Medicine Data Sheet. New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.nz (accessed 15 June 2010).
7. My Symbicort® SMART Asthma Action Plan. AstraZeneca Limited, PO Box 1301, Auckland.
8. Chapman KR, Barnes NC, Greening AP, et al. Single maintenance and reliever therapy (SMART): a critical appraisal. Thorax 2010;65:747-752.